Table 3.

Response rates in methylation biomarker defined subgroups of the treatment groups

	$n$	Cidofovir		Imiquimod		$p$
HPV 16 $L{1}^{\text{𝑙𝑜𝑤}}$	67	16/33	(48.5)	26/34	(76.5)	0.018
HPV16L1 $\mathrm{=}$ 0 & HPV16-ve	26	8/13	(61.5)	10/13	(76.9)	0.395
HPV16L1 $\mathrm{=}$ 0 & HPV16+ve	14	4/7	(57.1)	7/7	(100.0)	0.051
HPV16L1 $\mathrm{>}$ 0 & 24.9	27	4/13	(30.8)	9/14	(64.3)	0.082
HPV 16 $L{1}^{\text{ℎ𝑖𝑔ℎ}}$	65	19/32	(59.4)	14/33	(42.4)	0.172
HPV 16 $E{2}^{\text{𝑙𝑜𝑤}}$	85	21/46	(45.7)	24/39	(61.5)	0.144
HPV16E2 $\mathrm{=}$ 0 & HPV16-ve	26	8/13	(61.5)	10/13	(76.9)	0.395
HPV16E2 $\mathrm{=}$ 0 & HPV16+ve	33	9/17	(52.9)	9/16	(56.3)	0.849
HPV16E2 $\mathrm{>}$ 0 & 4	26	4/16	(25.0)	5/10	(50.0)	0.192
HPV 16 $E{2}^{\text{ℎ𝑖𝑔ℎ}}$	47	14/19	(73.7)	16/28	(57.1)	0.247
HPV 16 $E{2}^{\text{ℎ𝑖𝑔ℎ}}$or HPV 16 $L{1}^{\text{ℎ𝑖𝑔ℎ}}$	76	21/36	(58.3)	21/40	(52.5)	0.610
HPV 16 $E{2}^{\text{𝑙𝑜𝑤}}$and HPV 16 $L{1}^{\text{𝑙𝑜𝑤}}$	56	14/29	(48.2)	19/27	(70.4)	0.093
HPV 16 $E{2}^{\text{ℎ𝑖𝑔ℎ}}$and HPV 16 $L{1}^{\text{ℎ𝑖𝑔ℎ}}$	36	12/15	(80.0)	9/21	(42.9)	0.026
HPV 16 $E{2}^{\text{𝑙𝑜𝑤}}$or HPV 16 $L{1}^{\text{𝑙𝑜𝑤}}$	96	23/50	(46.0)	31/46	(67.4)	0.035

HPV 16 $E{2}^{\text{𝑙𝑜𝑤}}$ is 4% and HPV 16 $E{2}^{\text{ℎ𝑖𝑔ℎ}}$ is $⩾$ 4%. HPV 16 $L{1}^{\text{𝑙𝑜𝑤}}$ is 24.9% and HPV 16 $L{1}^{\text{ℎ𝑖𝑔ℎ}}$ is $⩾$ 24.9%. All $p$ values are unadjusted.